Loading
Life sciences · Journal article
Hormone and Metabolic Research · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Thyroidectomy and radioactive iodine therapy are definitive treatments for Graves’ disease, toxic nodular disease, and differentiated thyroid cancer. With improving survival rates and expanding indications for definitive therapy, a growing population is living for decades in a state of athyreosis requiring lifelong thyroid hormone replacement. Current management strategies largely emphasize serum thyroid-stimulating hormone targets and oncological surveillance, yet the long-term metabolic and physiological implications of chronic athyreosis remain incompletely explored. The potential longevity implications of long-term athyreosis are examined through a system-based framework integrating hormonal balance, mitochondrial regulation, metabolic adaptation, skeletal and cardiovascular health, and inflammatory signaling. This narrative review synthesizes evidence from endocrinology, metabolism, oncology, and aging research to evaluate physiological differences between endogenous thyroid hormone secretion and pharmacological replacement in athyreotic patients. Particular attention is given to tissue-level triiodothyronine availability, deiodinase activity, and downstream bioenergetic effects. Athyreotic patients lack intrinsic thyroidal triiodothyronine secretion and depend entirely on the peripheral conversion of levothyroxine to generate circulating and intracellular triiodothyronine. Emerging evidence suggests that levothyroxine monotherapy may not fully replicate physiological thyroid hormone dynamics in all individuals, potentially influencing mitochondrial biogenesis, resting energy expenditure, body composition, bone turnover, and cardiovascular remodeling. In thyroid cancer survivors, chronic thyroid-stimulating hormone suppression introduces additional considerations for skeletal and cardiac outcomes. Patients treated for autoimmune thyroid disease may also exhibit persistent immune dysregulation despite gland ablation. Athyreosis represents a distinct and permanent endocrine state with implications extending beyond biochemical euthyroidism. A system-based perspective that considers mitochondrial resilience, cardiometabolic integrity, skeletal preservation, and inflammatory tone may enhance long-term management strategies for this expanding survivorship population. Prospective studies are needed to clarify the impact of various thyroid hormone replacement paradigms on functional aging and longevity outcomes.